Biocon Limited Earnings Summary — Q1 FY2027
Biocon Reports Consolidation Growth in Biosimilars Amid Heavy Exceptional Integration Costs
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue declined 4.0% sequentially in Q1 FY2027.
- Revenue of ₹4,336 Cr is 10.0% higher year-on-year.
- Revenue has compounded at 4.6% annualised over the last 10 quarters.
- Net profit of ₹141 Cr is 349.4% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 2.0% annualised across the period.
- Operating margin stands at 19.5% in Q1 FY2027.
- Operating margin expanded by 11 bps year-on-year.
- Over the last two years operating margin has expanded by 147 bps.
- PBT margin is 2.9%.
- Expense growth of 9.9% remained below revenue growth of 10.0%.
- Operating profit of ₹847 Cr is 10.6% higher year-on-year.
- Operating leverage has been under pressure recently.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 62/100 (Healthy) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Stable | 4,336 | 4,517 | 4,173 | 4,296 | 3,942 | 4,417 | 3,821 | 3,590 | 3,433 | 3,917 |
| Expenses | Stable | 3,489 | 3,496 | 3,340 | 3,460 | 3,176 | 3,339 | 3,070 | 2,905 | 2,813 | 3,004 |
| Operating Profit | Stable | 847 | 1,020 | 834 | 835 | 766 | 1,078 | 752 | 685 | 620 | 913 |
| Operating Margin | Stable | 19.5% | 22.6% | 20.0% | 19.4% | 19.4% | 24.4% | 19.7% | 19.1% | 18.1% | 23.3% |
| Other Income | Volatile | 41 | -28 | -176 | 81 | 63 | 57 | 53 | 59 | 1,167 | 40 |
| Interest | Stable | 213 | 232 | 210 | 272 | 277 | 212 | 223 | 226 | 236 | 227 |
| Depreciation | Improving | 547 | 513 | 515 | 473 | 455 | 436 | 425 | 420 | 405 | 407 |
| Profit Before Tax | Volatile | 128 | 248 | -68 | 171 | 97 | 487 | 156 | 98 | 1,146 | 319 |
| Tax | Volatile | -9 | 49 | -16 | 39 | 8 | 27 | 75 | 71 | 284 | 96 |
| Net Profit | Improving | 141 | 126 | 144 | 85 | 31 | 345 | 25 | -16 | 660 | 136 |
| Net Margin | Improving | 3.3% | 2.8% | 3.5% | 2.0% | 0.8% | 7.8% | 0.7% | -0.5% | 19.2% | 3.5% |
Key Takeaways
- Biocon Biologics became a wholly owned subsidiary effective June 29, 2026, following a successful share swap transaction.
- The Biosimilars segment continues to lead growth, with revenue rising to ₹28,556 million, up 16% YoY.
- Services segment (Syngene) faced a sequential decline, dropping to ₹7,360 million from ₹10,365 million in the prior quarter.
- Operating margins were significantly impacted by high employee benefits and 'other expenses' associated with global business integration.
- Exceptional items totaling ₹135 million were recognized this quarter, primarily related to employee termination benefits at Syngene.
- The company completed several debt-related moves including the conversion of Optionally Convertible Debentures (OCDs) and Compulsorily Convertible Debentures (CCDs) in May 2026.
Management Guidance
Management remains focused on the 'Biocon 2.0' strategy, aiming to leverage the fully integrated Viatris biosimilars acquisition for direct commercialization in advanced markets while managing the high debt profile.
Sentiment Shift
Improving
While margins remain thin and debt remains a concern, the successful full consolidation of the Biologics unit and YoY growth in the core Biosimilars segment indicates a stabilizing platform for future recovery.
Outlook
The company is transitioning through a high-investment phase; future performance depends on maintaining the momentum of Biosimilar approvals and successfully reducing leverage from recent heavy M&A activity.
From the Annual Report (Key Quotes)
“Biocon Biologics has become a wholly owned subsidiary of the company w.e.f. June 29, 2026.”
“The group recorded acquisition of equity shares in its subsidiary as an equity transaction.”
“The figures for the quarters ended March 31, 2026 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Biocon Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.